Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating.

Meeting to be held in Boston on February 6 hosted by Cantor Fitzgerald. Maximize Your Portfolio with Data Driven Insights:Leverage the power of ...

Stratasys (NASDAQ:SSYS – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They currently have ...

Howard Lutnick, the chairman of Cantor Fitzgerald and nominee for U.S. Commerce Secretary, faced questioning from Senate Democrats regarding the financial firm's investment in Tether, the entity ...

Howard Lutnick, chairman and CEO of investment firms Cantor Fitzgerald and BGC Group, told the U.S. Senate Committee on ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

Equities research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for KLA in a note issued to investors on Friday, January 31st. Cantor Fitzgerald analyst C. Muse ...

Seventh Circuit upholds forfeiture-for-competition provision in restricted stock unit agreement - A Seventh Circuit panel, in ...

Cantor Fitzgerald LP’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge.

Howard Lutnick, President Donald Trump's nominee for Commerce Secretary and CEO of Cantor Fitzgerald, says the firm has no ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...